You just read:

Uptake of Biogen's Tecfidera and Increased Availability of Merck KGaA's Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva's Copaxone

News provided by

Spherix Global Insights

Oct 09, 2018, 04:30 ET